The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to<a href="https://solaci.org/en/2015/06/24/danami3-primary-angioplasty-to-culprit-vessel-versus-multivessel-guided-by-ffr/" title="Read more" >...</a>

Article Up to 50% of acute myocardial infarctions are associated to mitral regurgitation of some degree and 10% of these cases present, at least, moderate regurgitation. Ischemic mitral regurgitation is associated to an increase of mortality and morbidity. For surgical patients with moderate regurgitation, the benefits mitral valve repair remain unclear.&nbsp; 301 patients were randomized<a href="https://solaci.org/en/2015/06/24/mitral-valve-repair-in-moderate-ischemic-mitral-regurgitation/" title="Read more" >...</a>

This double-blind study included 21162 patients with a history of acute myocardial infarction randomized to ticagrelor 90 mg e/12 h, ticagrelor 60 mg e/12 h or placebo. All patients received aspirin and had additional risk factors such as age or diabetes. The history of infarction should be between one and three years before being included<a href="https://solaci.org/en/2015/06/24/pegasus-timi-54-ticagrelor-plus-asa-in-stable-patients/" title="Read more" >...</a>

The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an ST-segment elevation acute myocardial infarction. Pre-hospital management that could improve coronary reperfusion and events like death or stent thrombosis was not studied. 1862 patients were included suffering ST-segment elevation acute myocardial<a href="https://solaci.org/en/2015/06/24/atlantic-administration-of-ticagrelor-in-the-ambulance-versus-in-the-cath-lab/" title="Read more" >...</a>

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7 centers suffering ST-segment elevation acute myocardial infarction referred for primary angioplasty randomized to treat only the culprit artery (n = 146) versus complete revascularization (n = 150).&nbsp; In the culprit artery<a href="https://solaci.org/en/2015/06/24/culprit-complete-revascularization-versus-culprit-artery-of-infarct-only/" title="Read more" >...</a>

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate &ge; 70 bpm.<a href="https://solaci.org/en/2015/06/24/signify-ivabradine-does-not-reduce-events-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an<a href="https://solaci.org/en/2015/06/24/bright-bivalirudin-versus-heparin-versus-heparin-plus-tirofiban-in-primary-angioplasty/" title="Read more" >...</a>

This study included 201 patients suffering ST-segment elevation acute coronary syndrome and randomized to the use of optical coherence tomography (OCT) versus conventional angiography for the procedure. OCT-guided group used more stents per patient (1.4 versus 1.2, p = 0.03) and greater release pressure. During control OCT suboptimal results were found in a third of<a href="https://solaci.org/en/2015/06/24/oct-stemi-primary-angioplasty-guided-by-oct/" title="Read more" >...</a>

There are experimental studies suggesting that metformin admin before and during ischemia and reperfusion could help to preserve left ventricular function regardless of glycometabolic state.In observational studies, the concomitant use of metformin is associated with a lower peak CK MB and troponin.380 nondiabetic patients undergoing primary angioplasty for acute coronary syndrome study with ST segment<a href="https://solaci.org/en/2015/06/24/gips-iii-metformin-does-not-improve-ejection-fraction-in-non-diabetic-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during the ischemic period could significantly reduce infarct size in experimental studies in humans, but the results were inconsistent. This study tested the hypothesis that intravenous nitroprusside infusion immediately before the opening<a href="https://solaci.org/en/2015/06/24/niami-nitroprusside-infusion-prior-to-primary-angioplasty/" title="Read more" >...</a>